TheraRadar
← Back
Data updated: Jul 17, 2026

PLX PHARMA

Pharma
MetabolicGastroenterology Execution: Excellent

PLX PHARMA is a pharmaceutical company focused on Metabolic, Gastroenterology. Key products include VAZALORE.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PLX PHARMA at a Glance

  • Strong track record with 100% execution quality across 10 trials
  • Fast trial execution (5 months median completion)

PLX PHARMA's Key Drugs

PLX PHARMA's core commercial portfolio centers on VAZALORE, spanning Metabolic and Gastroenterology — its most strategically important drugs approved in the last 15 years.

VAZALORE
Pain
Approved 2013

PLX PHARMA's Recent FDA Approvals

New NDA/BLA approvals for PLX PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PLX PHARMA's Therapeutic Areas

PLX PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 62%
0 drugs Phase 3: 2
Gastroenterology 38%
0 drugs Phase 2: 2 Phase 1: 1

PLX PHARMA's Top Competitors

PLX PHARMA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Takeda, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Gastroenterology, Metabolic
Takeda big-pharma
Metabolic, Gastroenterology
ASTELLAS specialty
Metabolic, Gastroenterology
Amgen biotech
Metabolic, Gastroenterology
EMD SERONO INC biotech
Metabolic, Gastroenterology

PLX PHARMA Pipeline Snapshot

PLX PHARMA has 5 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 2 Phase 2 and 1 Phase 1.

2
Phase 3
2
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VAZALORE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/2 completed
  • • Speed: 5 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges